The retrospective analysis also confirmed the findings of previous studies, which demonstrated that PSMA PET has an additive value and increases the negative predictive value and sensitivity for clinically significant prostate cancer when combined with mpMRI. This evidence concerns the gene FOLH1 and prostate carcinoma.